Capricor Therapeutics, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Capricor Therapeutics, Inc. (CAPR) holds an ST Score of 39.3 out of 100 (C), with its strongest factor being Forecast (B) and its weakest Sentiment (F). Analysts rate CAPR Buy across 10 ratings with a $12.70 average price target (+0.4% vs the current $8.90).
- Strongest
- ForecastB
- Weakest
- SentimentF
All factor grades
- ForecastB
- ValuationB-
- ProfitabilityB-
- MomentumB-
- Financial StrengthC
- GrowthD+
- SentimentF
- Piotroski2/9
Contact
CAPR stock: frequently asked questions
What is CAPR's ST Score?
Capricor Therapeutics, Inc. (CAPR) has an ST Score of 39.3 out of 100, an overall grade of C. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is CAPR a buy, sell, or hold?
Wall Street's consensus rating on CAPR is Buy based on 10 analyst ratings. Our own ST Score grades it C (39.3/100). This is data, not investment advice — always do your own research.
What is CAPR's valuation grade?
Capricor Therapeutics, Inc. (CAPR) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is CAPR's growth grade?
Capricor Therapeutics, Inc. (CAPR) earns a growth grade of D+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is CAPR's profitability grade?
Capricor Therapeutics, Inc. (CAPR) earns a profitability grade of B-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is CAPR's financial strength grade?
Capricor Therapeutics, Inc. (CAPR) earns a financial strength grade of C, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for CAPR?
The average analyst price target for Capricor Therapeutics, Inc. (CAPR) is $12.70 from 10 analysts, which is +0.4% versus the recent price of $8.90.
What is CAPR's Piotroski score?
Capricor Therapeutics, Inc. (CAPR) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.